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S U M M A R Y
The dominant approach to decision-making in public health policy for infectious diseases relies heavily
on expert opinion, which often applies empirical evidence to policy questions in a manner that is neither
systematic nor transparent. Although systematic reviews are frequently commissioned to inform
speciﬁc components of policy (such as efﬁcacy), the same process is rarely applied to the full decision-
making process. Mathematical models provide a mechanism through which empirical evidence can be
methodically and transparently integrated to address such questions. However, such models are often
considered difﬁcult to interpret. In addition, models provide estimates that need to be iteratively re-
evaluated as new data or considerations arise. Using the case study of a novel diagnostic for tuberculosis,
a framework for improved collaboration between public health decision-makers and mathematical
modellers that could lead to more transparent and evidence-driven policy decisions for infectious
diseases in the future is proposed. The framework proposes that policymakers should establish long-
term collaborations with modellers to address key questions, and that modellers should strive to provide
clear explanations of the uncertainty of model structure and outputs. Doing so will improve the
applicability of models and clarify their limitations when used to inform real-world public health policy
decisions.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Public health policy decisions must balance a range of scientiﬁc,
budgetary, social, and political considerations. Ideally, each of
these elements should be considered in a transparent fashion
before reaching a decision or implementing a speciﬁc policy. While
socio-political considerations will always be somewhat subjective,
scientiﬁc evidence can – in theory – be used to evaluate the
potential epidemiological or economic impact of alternative* Corresponding author. Tel.: +44 (0)208 383 2730.
E-mail address: g.knight@imperial.ac.uk (G.M. Knight).
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).decisions. For example, in the setting of a high-proﬁle outbreak,
the probability of making political gains or alleviating public fears
is not objectively quantiﬁable (despite their importance to the
decision-making process), but scientiﬁc outcomes, such as
potential trajectories of the outbreak under different policy
decisions, can be estimated quantitatively with appropriate tools
using the best available data as inputs, such as the known
incubation period.
In the realm of infectious diseases, the tools for integrating and
translating scientiﬁc data into policy-relevant outcomes are often
classiﬁed in the domain of ‘mathematical models’,1,2 which are
deﬁned here as quantitative frameworks for the analysis of
dependent happenings (events where the number affected at one
time depends on the number already affected3). For example,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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ical terms such as the rate of movement from an infectious to a
treated state. These models have the ability to translate existing
scientiﬁc evidence into projected outcomes at the population level
for both endemic diseases like tuberculosis (TB) and epidemic
situations such as the Ebola virus disease (EVD) outbreak in West
Africa in 2014–2015,4,5 in a way that is transparent and veriﬁable
or refutable by external observers. These estimates can also help
with clinical decision-making at the individual level, to improve
patient outcomes.
Unfortunately for most public health decisions regarding the
control of infectious diseases, such models are seldom constructed
– and when they are, they often have limited impact upon the
decision-making process. This is likely due to several factors,
including perceptions that models are too complex to understand
or too dependent on assumptions, coupled with a history of
insufﬁcient communication between public health practitioners
with speciﬁc policy questions and modellers with the quantitative
tools to address them.
Here, the potential role of mathematical modelling in decision-
making for health policy in the realm of infectious diseases is
explored, and key reasons why mathematical models have
historically not fulﬁlled this potential are evaluated. To do this,
the current status of modelling in public health decision-making is
ﬁrst outlined and a case study modelling question described.
Details of how to construct a relevant model and how to link it to
policy are then given, and some of the potential limitations and
challenges of using modelling described. Finally, a framework by
which improved collaborations between public health stake-
holders and modellers may broadly beneﬁt public health is
proposed.
2. Current role and potential opportunities for modelling in
public health decision-making
The use of structured frameworks for applying evidence to
public health decision-making is well established.6 For example,
the World Health Organization (WHO) advocates the use of the
GRADE process,7 which is a framework that connects a public
health question to an evidence-based analysis and recommenda-
tion.8 The United States Preventive Services Task Force (USPSTF)
similarly uses decision-making algorithms to assess the level and
quality of evidence to support the introduction of speciﬁc
interventions.9 However, these frameworks for using scientiﬁc
evidence to support policy decisions often lack quantitative
assessments of how different decisions will impact health at a
population level.
This is especially true in the realm of infectious diseases, where
the dynamics of transmission may cause great disparity between
the individual-level beneﬁt or harm of an intervention (for
example, side effects of a vaccine for a rare disease such as polio
that may outweigh an individual’s risk of contracting the disease)
and its population-level impact (for example, maintaining
elimination of polio through herd immunity). As a result, in
settings where population-level beneﬁts are unproven, interven-
tions with strong scientiﬁc evidence for individual effectiveness
may be recommended over those with a potentially dramatic
impact for populations. This decision-making process, if unin-
formed by insight at the population or system level (as provided by
models), may perversely result in outcomes that are good for
certain people, but bad for the population as a whole.
Models can address this knowledge gap by estimating the
effects of interventions when the collection of population-level
empirical evidence (e.g., from cluster-randomized trials) is
infeasible, unethical, or untimely. For example, mathematical
models suggested that universal voluntary HIV testing andimmediate antiretroviral therapy (ART) might dramatically reduce
future HIV transmission,10–12 even though the individual-level
effectiveness of ART at higher CD4+ T-cell counts is small,13 and
reduced transmission at the population level is difﬁcult to prove
empirically. By projecting population-level effects of potential
interventions, the models informed not only key policy decisions
but also the design of future clinical trials.14
Despite the potential impact that model outputs can have on
public policy decisions, the use of models by public health
decision-makers has traditionally been limited.2 Many public
health and policy decisions must be reached rapidly, in too short a
time for new models to be developed, parameterized, and
calibrated. Modellers must therefore achieve a balance between
anticipating future policy questions (in which case models may
ultimately not speak to the speciﬁc policy question at hand) and
responding to existing questions (in which case models may be
constructed too late to inform policy decisions). In addition, as
mentioned above, complex models that are poorly presented are
unlikely to be used by time-pressured policymakers. Furthermore,
it remains unclear in most settings how to weigh evidence from
models against other epidemiological and clinical data. As
described below, all models must make certain assumptions and
manage attendant uncertainty. These aspects of models are often
not well-understood by public health stakeholders, and as a result,
model outputs may be seen as difﬁcult to interpret and
untrustworthy. A framework by which modellers and decision-
makers can work together to more appropriately incorporate
evidence from infectious disease models into public health
decisions, without over- or underemphasizing the importance of
those models, is proposed here.
3. Modelling infectious diseases for policy: the example of a
rapid TB diagnostic
To demonstrate the utility and process by which mathematical
models can inform infectious disease policy, the case study of a
new molecular diagnostic test for TB is used: the Xpert MTB/RIF
test (Xpert).15 Xpert provides a comparatively rapid, point-of-
treatment diagnosis in under two hours, if placed in settings where
individuals present for initial TB diagnosis and/or follow-up
evaluation. Xpert is also substantially more sensitive than the
most widely used diagnostic test for TB worldwide (sputum smear
microscopy). However, at over 10 times the cost of sputum smear
microscopy (which costs less than $2 fully-loaded per test,
compared to about $20 for Xpert), scale-up of Xpert has the
potential to dramatically increase the cost of TB control in high-
burden settings.
The key policy-related questions around the use of Xpert are the
following: Do the clear individual-level beneﬁts of improved
diagnosis translate into population-level effects on transmission,
and if so, would scale-up of Xpert have sufﬁcient impact to justify
the added cost (i.e., would Xpert be cost-effective)? These
questions can be, and have been, addressed effectively using
mathematical modelling.
In the case of Xpert, an initial modelling study projected the
impact on TB-associated morbidity and mortality, and cost-
effectiveness, in ﬁve countries of southern Africa.16 This study
adopted a regional approach, which allowed the authors to use a
single model framework (due to similar epidemics across the ﬁve
countries) and existing data (which are reported on the national
level). A global model would likely have required more model
complexity, whereas a sub-national model might have been
limited by available data or generalizability. The authors aimed
primarily to publish their results in the scientiﬁc literature,
although the model has subsequently been used in country-level
discussions and extended to other regions. The model predicted a
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transmission and mortality, based on the assumption that
increased rapid diagnosis would increase treatment rates. In the
absence of pre-existing data, this model had to make a number of
reasonable simplifying assumptions, including the proportion of
individuals with TB who would ultimately be diagnosed by the
existing algorithm in the absence of Xpert and the speed at which
that diagnosis might happen. These results – which reﬂected the
best available data and assumptions at the time – were used to
support policy recommendations to scale up Xpert in the region
and worldwide.
Subsequent clinical trials revealed that Xpert did not identify
many more patients than were already being started on treatment,
due to unexpectedly high levels of empiric treatment practices in
TB-endemic settings.17,18 Using this new information, the model
was then revised to account for empiric treatment practices, and
new estimates predicted a much smaller impact of Xpert.17
This case study illustrates the ability of models to iteratively
incorporate updated data, leading to better estimates and
highlighting existing weaknesses in both model assumptions
and available data over time. A pertinent translation of individual-
level effect to population impact is also displayed. Unfortunately,
the case study also demonstrates the challenges in linking model
results to policy. Major obstacles exist to the implementation of
Xpert, especially in trying to use Xpert as a true point-of-care
test.19 Nevertheless, despite its impact on population health being
initially relatively uncertain, Xpert has received strong support
from policymaking bodies such as the WHO,20 based primarily on
systematic reviews of sensitivity and speciﬁcity. This recommen-
dation places pressure on many high-burden countries to scale
Xpert up,21 and at tremendous expense. Even in light of emerging
data and updated model projections that suggest Xpert may not
improve population-level outcomes,17 recommendations to im-
plement Xpert have become increasingly strong, partially due to
political momentum and the known individual-level beneﬁts of
Xpert.
The policy–modelling disconnect in recommendations for
Xpert contrasts, for example, with that for systematic screening
for TB in high-risk populations. Systematic screening for TB has
been shown in multiple mathematical models to have a potentially
dramatic impact at the population level,22-25 but the beneﬁts of
systematic screening at the individual level are difﬁcult to prove.26
The recommendation for systematic screening is therefore much
less enthusiastic.27 As a result of this discrepancy between
individual-level evidence (which is easier to collect directly but
arguably less important to public health) and population-level
evidence (which is difﬁcult to collect directly and thus often
requires models but is critical to public health decision-making),
many countries are pressured to implement Xpert rather than
systematic screening. This pressure exists despite the evidence
from models that systematic screening might have much greater
impact on reducing TB at the population level – and potentially at a
more favourable cost–effectiveness ratio.23
In summary, as shown by the case study of Xpert, modelling
interventions is often the only way to evaluate the comparative
effectiveness (and cost-effectiveness) of interventions at the
population level in the short term. In doing so, models may not
only help to prioritize those interventions that might have greatest
impact at the population level, but may also identify the data
elements needed to better inform estimates of such impact for
different public health policies.28 This process – which ideally
occurs iteratively as new data emerge – can lead to better
alignment between research efforts and policy priorities. However,
major obstacles exist to the implementation of this process, and
current practice continues to prioritize infectious disease inter-
ventions with more beneﬁt for individuals than for populations.4. Building useful models
Developing a useful model includes identifying, in sequence (1)
a useful question and its epidemiological context, (2) a framework
through which that question could be addressed, (3) the
parameters required to address the speciﬁed question using that
framework, and (4) the empirical evidence available to inform
meaningful values of those parameters (for examples and further
details see publications by Vynnycky and White29 and Keeling and
Rohani30). Once a question, framework, parameters, and empirical
evidence have been identiﬁed, the model can then be used to
inform decision-making by projecting the potential outcomes
associated with different policy decisions. For example, in the
Xpert case study, the question of interest was how big would the
impact of this new diagnostic test be? The epidemiological setting
was ﬁve countries with high TB incidence.16 The framework
utilized was a transmission model that used both natural history
and TB control parameters, such as treatment success, informed by
country-level TB programme data.
For models to be useful to decision-makers, they must be both
relevant and methodologically sound. In general, useful models are
built to answer a key question that should guide the structure and
complexity of the model (rather than the model determining the
question). One such question might be to evaluate the expected
epidemiological and economic impact of different strategies for
scaling up Xpert for TB diagnosis (e.g., centralized or in individual
clinics), or the required bed capacity during the recent EVD
outbreak.31 Deﬁning a central question also helps to inform the
structure of the model, which should incorporate relevant
scientiﬁc data (e.g., transmission rates, existing levels of infection
control and treatment). The epidemiological setting is also
important; for example, a model of implementing Xpert should
include not only the sensitivity and speciﬁcity of the test but also
the diagnostic processes, underlying disease prevalence, and
clinical algorithms in the chosen setting. A model of TB diagnosis
in the USA would need to account for immigration, for instance,
whereas a model of TB in Sub-Saharan Africa would require a more
detailed description of ART scale-up.16 In some cases, the same
model structure can be modiﬁed to explore ‘ﬁrst-pass’ results
across a range of settings and interventions;32 in other cases (or
when more precisely calibrated results are needed), separate
models will be required for each setting.
In general, models allow for an exploration of the system and
give a holistic picture of the realm of possible outcomes. As such,
uncertainty and sensitivity analyses around the main components
of the model are critical. Uncertainty analysis translates uncer-
tainty in model ‘inputs’, such as the proportion of patients
accessing different diagnostic services, into uncertainty in model
‘outputs’, such as the impact of a new diagnostic on mortality.
Sensitivity analyses aim to attribute portions of this uncertainty to
speciﬁc parameters. In a one-way sensitivity analysis, for example,
a key parameter (such as the TB transmission rate) might be set
sequentially to its highest or lowest plausible values, and the
model results assessed at each of those points. In the case of Xpert,
population-level impact has been shown to be very sensitive to
existing levels of empirical therapy for TB.33,34 Broader consider-
ation of model uncertainty would explore the impact of a range of
plausible empirical treatment levels as well as other model
parameters (for example, transmission rates) or indeed do a more
comprehensive sampling over all parameters.35
Ultimately, the estimates of any model can only be as accurate
as their supporting data, but models can also describe that
uncertainty to decision-makers, allowing them to make the most
appropriate decisions given existing, imperfect evidence. As
such, modelling results with wide conﬁdence intervals that reﬂect
this uncertainty are often valuable to policymakers, as they
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where false conﬁdence in predictions is gained via modelling based
on strong unsupported assumptions, must be avoided despite the
temptation of the ‘clarity’ of results that such assumptions can
provide.
5. Linking model results to public health policy around
infectious diseases
Models can inform infectious disease public health policy in at
least three ways (see Figure 1). Firstly, models can systematically
use epidemiological data to better understand the larger systems
in which policy decisions must be made. For example, mathemati-
cal models of Xpert scale-up in Africa have suggested that baseline
diagnostic patterns affect the incremental beneﬁt of a novel, more
sensitive test,34 thereby suggesting that policymakers should
target Xpert roll-out to areas with the weakest existing diagnostic
systems.
Secondly, as described above in the case of universal HIV testing
and treatment, models can apply a transparent framework to
compare the potential population-level impact of interventions in
situations where collecting empirical evidence might be logisti-
cally, monetarily, or ethically infeasible.37,38 Even when broader
empirical studies are feasible, interim policies must nonetheless be
set; models can help these policies make maximum use of existing
evidence before deﬁnitive results are known.
For example, modelling estimates for the recent EVD outbreak
in West Africa published in September 2014 predicted that without
interventions, Liberia and Sierra Leone would have approximately
550 000 reported Ebola cases by January 2015.39 The predictions
over a shorter timeframe were closer to what actually occurred; for
estimates of case numbers by September 2014, the model
overestimated the number of cases by only 8.8% in Liberia, and
underestimated the number of cases by 7.6% in Sierra Leone. The
later projections to January 2015 were substantially less accurate.
These results, however, demonstrated at the time what most
needed to be done to control the outbreak. Thus this is an example
of where modelling results may appear ‘wrong’ but can still be
useful. Furthermore, the results made under the assumption of no
intervention highlight the impact that outbreak control interven-
tions had on the magnitude of the outbreak – and these could later
be compared to an alternative model structure that incorporates
those interventions to further evaluate their impact. By highlight-
ing how serious things could be if nothing was done, models
emphasized the need for control interventions and the aspects ofRoles 
1. Understanding disease systems: Improv 
epidemic systems so that public hea lth 
drivers  of epidemic spread
1. Projecting impac t: Ev aluate and  compa 
economic impac t of altern ative public h
2. Driv ing research:  Revea l data  gaps  that 
offi cials to  make more evidence-based 
Challeng es 
1. Complexity of model structur e and  in te
2. Uncert ain ty of model outputs du e to da 
3. Lac k of coordination betwee n policy qu 
4. Limited com munication between mode 
Figure 1. Roles and challenges of infectious diseathose interventions that might be most important from an
epidemic control perspective.
Thirdly, modelling can point to data gaps that, if ﬁlled, could
better assist decision-making and control of infectious diseases in
the future. For example, TB models might ﬁnd that the comparative
impact of Xpert scale-up strategies depends strongly on the
amount of ongoing TB transmission in a community, which in
many places may not be known.6 These results could motivate
further data-gathering activities (e.g., molecular epidemiological
characterization of a community,40,41 or synthesis of existing
programmatic data on TB incidence42) that could help to improve
decision-making related to Xpert scale-up in the future. For the
spread of rubella, modelling has already led to the collection of
new missing data.43
In each of these cases, mathematical models provide public
health decision-makers with key pieces of knowledge that can
inform evidence-based decision-making. Furthermore, unlike
expert opinion (which often holds sway purely on the basis of
reputation or existing dogma), models accomplish this task in a
way that is quantitative and open to questioning (or modiﬁcation)
by others in the ﬁeld. When a model’s structure, methods,
assumptions, and parameters are laid out in a reproducible
manner with direct communication and guidance to those with
less methodological expertise, their results should be transparent
and accessible rather than being perceived as a ‘black box’ that is
susceptible to manipulation and is too difﬁcult to understand.
6. The challenges of using models and approaches to
addressing them
These potential beneﬁts of infectious disease models can be
offset by excess complexity.37 While in theory, models are fully
transparent, many models are made so complex that few outside
the modelling community can fully understand their mechanics. In
addition, while models should be tailored to answer a speciﬁc
policy question of interest, they are often presented in such a
fashion that does not speak readily to key policy decisions.37
Modellers must strive to produce transparent outputs that can
directly inform the policymaking process, even when this requires
some simpliﬁcation to be made.
An important way to improve transparency is to publish the
raw data as well as any modelling code.44Whether provided in the
appendix of the publication or in online format, this would provide
readers with access to the model and the ability to closely review
its methods, thus making a more informed determination as toe our und erst anding of infectious dise ase 
prac tition ers  ca n better ta rget key 
re the  potential  epidemio logical and 
ea lth in terv ent ions
, if  filled,  would  enable  public hea lth 
decis ions in  the future
rp retation
ta limitations
est ions and  model  stru ctur e/ou tputs
lers and  stak eholde rs
se models for public health decision-making.
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and code would also allow for the model to be improved and
developed iteratively by others in the modelling community to
answer other policy-relevant questions.
In addition, care must be taken when broadly applying a model
speciﬁcally structured to answer a certain question. For example, a
modelling evaluation of Xpert scale-up across southern Africa16 is
unlikely to provide useful guidance on where to place Xpert
machines in the USA,45 or whether to supplant other funds to pay
for Xpert testing.46,47
However, models can be, and often are, reconstructed as new
evidence or considerations come to light. The development begins
with models that provide initial insight; such initial models are
then gradually replaced by more complete models that incorporate
updated information. This process of iteratively evaluating
modelling output provides a framework in which to place new
evidence and improves our understanding of both the problem and
the utility of the modelling tool being applied. While the need for
such iteration can be seen as a problem with the initial model or
input data, it is more appropriately seen as reﬂecting the natural
course of scientiﬁc inquiry, in which better data and better tools to
utilize those data are continually being developed.
Presenting the uncertainty around modelling results, as
described above, presents a further challenge as it often reﬂects
limited available data on key parameters. In such cases, modellers
should honestly portray this uncertainty rather than providing
results that appear more reliable, and policymakers should make
decisions based on this uncertainty rather than requesting results
that are more precise. Not including such uncertainty may beFigure 2. Proposed framework for interaction between infectious disease modellers and p
relevant public health questions for modellers to address and the existing data that can b
with modellers, further discussion should pertain to the relevant model structures best su
communication, evidence gaps can be identiﬁed and modelling outputs can be reviewed
model is reﬁned and ﬁnalized, the outputs can be used to support data-informed decisio
and mathematical modellers can ensure that models have optimal impact on evidencejustiﬁed in speciﬁc cases39 – such as when the infectious disease
situation being modelled (e.g., when considering just a ‘no
intervention’ scenario) is unrealistic and speciﬁc policy decisions
are not based on this quantitative value – but is generally not
recommended.
There are also signiﬁcant ethical considerations that must be
taken into account when using the results of mathematical models
to design public health interventions. These include considering
the values and preferences of the target population as well as the
available resources.48 Determinants of health behaviour must be
viewed in a social context, including the cultural beliefs, historical
patterns, and choices available to the local population. If applied in
a vacuum, modelling results may not be relevant to the target
population and the estimated impact of a chosen intervention will
likely not be realized.
7. Recommendations for a future framework
How can we improve the utility of modelling for infectious
disease relevant to public health decision-making in the future?
One important component of any such strategy should involve
ongoing collaboration and interaction between infectious disease
modellers and public health stakeholders. Such communication
and collaboration enables decision-makers to appropriately
understand the complexity of model structure and uncertainty
in modelling results, and modellers to inform additional reﬁne-
ments or data-gathering efforts to reduce that complexity and
uncertainty. In addition, both modellers and public health policy-
makers must view the results of models within the social contextublic health practice. Stakeholders in public health practice should identify the key
e used to inform model structure and parameters. Once shared and communicated
ited to address the question and the required inputs. Subsequently, through ongoing
 and understood in the context of model uncertainty and generalizability. Once the
n-making. In this way, long-term collaboration between public health practitioners
-based public health decision-making.
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modelling results to speciﬁc settings. Fostering such collaboration
will improve the availability of models to public health practi-
tioners, as well as the quality of model structure and relevance of
results. It will also improve the likelihood that the perspectives and
needs of all critical stakeholders are included.
To promote such public health stakeholder collaboration and
optimize the role mathematical modelling can have in public
health decision-making in the ﬁeld of infectious diseases, an
iterative process for model development is recommended
(Figure 2). The key stages in this process are: (1) Policymakers
engage modellers early in the decision-making process and inform
them of the key public health questions that are being considered
in a given population and/or clinical setting. (2) Modellers use this
information to construct models that are most likely to effectively
address these questions. (3) Modellers strive to reduce, or fully
justify, the complexity of their models and explain the context and
uncertainty of their outputs to decision-makers and others who
could openly interrogate their methods. (4) Decision-makers seek
to incorporate model results into their decision-making process
(including decisions for more data gathering) and inform
modellers of where model structures, outputs, and uncertainty
could be reﬁned for future decision-making.
To succeed in this endeavour, it is important that modellers and
decision-makers build mutual trust over time; these steps are
difﬁcult to complete in a ‘one-off’ fashion for each new question
that arises. Platforms for such interaction, such as conferences and
workshops, should be developed and promoted to stimulate
discussion and interaction around the important questions and
how to address them, including how to share key data. As effective
communication is only possible when modellers and stakeholders
speak the same ‘language’, it is critical that these communities
work together to establish long-term collaborative relationships.
As an example of such longer-term collaboration between
infectious disease modellers and infectious disease policymakers,
the TB public health community has established platforms where
engaged stakeholders can interact. For example, the TB Modelling
and Analysis Consortium (TB MAC) brings together quantitative
researchers, policymakers, TB programmes, and donors to identify
TB control questions that require modelling input.49 Discussion
and interaction between TB control stakeholders is also supported
by the TB Modelling group at Johns Hopkins,50 which holds
frequent international conference calls to examine the latest
research and areas of interest. Such multidisciplinary collaboration
is also being seen in other infectious disease ﬁelds, where
modelling studies have been used to assist public health
interventions and policy-making decisions around HIV, inﬂuenza,
and EVD.51–53 While such relationships take time to build, are
difﬁcult to incentivize from both the academic and public health
perspectives, and may not yield immediate results, increased
communication between modellers and public health policy-
makers is arguably the only viable path towards bringing the
wealth of existing epidemiological evidence to bear in making
public health decisions for infectious diseases.
8. Conclusions
Infectious disease modelling can provide important and useful
data to inform public health policy by improving our knowledge of
epidemic disease spread, comparing the impact of potential public
health interventions and understanding gaps in existing data used
to inform public health decision-making. For models to be most
useful, challenges in applying modelling results to public health
practice, including the complexity of model structure and
uncertainty of model outputs and their relevance to important
policy questions, must be understood and considered. Whilemodelling will not provide all the answers for public policy, it can
provide useful quantitative evidence when large clinical studies
are not possible or are still underway. A framework that can be
used to improve the process of applying modelling to public health
decision-making for infectious diseases is proposed. Collaboration
between public health stakeholders and modellers is essential to
heighten the transparency and public health relevance of models,
to optimize the use of epidemiological data for decision-making,
and to develop policies that incorporate scientiﬁc evidence to
improve the control of infectious diseases worldwide.
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